for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Immunomedics, Inc.

IMMU.O

Latest Trade

85.53USD

Change

0.19(+0.22%)

Volume

9,245,738

Today's Range

85.26

 - 

85.78

52 Week Range

8.80

 - 

86.91

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
85.34
Open
85.70
Volume
9,245,738
3M AVG Volume
88.07
Today's High
85.78
Today's Low
85.26
52 Week High
86.91
52 Week Low
8.80
Shares Out (MIL)
231.16
Market Cap (MIL)
19,726.92
Forward P/E
-76.42
Dividend (Yield %)
--

Next Event

Immunomedics Inc to Discuss Results from Trodelvy Study - Conference Call

Latest Developments

More

Gilead Sciences Says If Deal Is Terminated Under Certain Circumstances, Immunomedics Will Pay Co A Termination Fee Of About $732.1 Mln

HBM Healthcare Investments: Gilead Sciences To Acquire HBM Portfolio Company Immunomedics

Gilead Sciences Says To Acquire Immunomedics For $88 Per Share In Cash

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Immunomedics, Inc.

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.

Industry

Biotechnology & Drugs

Contact Info

300 the American Rd

MORRIS PLAINS, NJ

07950-2460

United States

+1.973.6058200

https://www.immunomedics.com/

Executive Leadership

Behzad Aghazadeh

Executive Chairman of the Board

Usama Malik

Chief Financial Officer, Chief Business Officer

Kurt J. W. Andrews

Chief Human Resource Officer

William Fricker

Principal Accounting Officer

Jared Morris Freedberg

General Counsel, Corporate Secretary

Key Stats

2.56 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.1K
EPS (USD)

2017

-1.470

2018

-1.780

2019

-1.840

2020(E)

-1.115
Price To Earnings (TTM)
--
Price To Sales (TTM)
968.48
Price To Book (MRQ)
33.22
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-49.41
Return on Equity (TTM)
-45.48

Latest News

Latest News

Immunomedics drug Trodelvy extends survival in breast cancer patients

Immunomedics Inc's cancer drug Trodelvy, which received accelerated U.S. regulatory approval in April, extended survival time in previously treated patients with an advanced form of breast cancer in a clinical trial, the company said on Saturday.

Immunomedics' cancer drug helps reduce tumor size in early-stage study

Immunomedics, Inc said on Friday its treatment, Trodelvy, helped partially reduce tumor size in an early-stage study testing it in brain cancer patients.

Immunomedics reports promising early-stage data from cancer drug study

Immunomedics, Inc said on Friday its treatment, Trodelvy, helped partially reduce tumor size in an early-stage study testing it in brain cancer patients.

Gilead bolsters cancer portfolio with $21 billion acquisition of Immunomedics

Gilead Sciences Inc will acquire biotech company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a joint statement on Sunday.

Gilead's shares rise after $21 billion deal for Immunomedics

Shares of Gilead Sciences Inc <GILD.O> rose 3.2% on Monday, reversing their premarket losses as investors shrugged off concerns over the steep premium the U.S. drugmaker was willing to pay for Immunomedics Inc <IMMU.O>.

Gilead's shares fall on concerns over high premium cancer deal

Shares of Gilead Sciences Inc fell nearly 2% on Monday as investors questioned the steep premium the U.S. drugmaker was willing to pay for Immunomedics Inc.

CORRECTED-UPDATE 2-Gilead to buy cancer drugmaker Immunomedics for $21 bln

Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a joint statement on Sunday.

Gilead nears deal to buy Immunomedics for more than $20 billion - WSJ

Gilead Sciences Inc <GILD.O> is nearing a deal to buy biopharmaceutical company Immunomedics Inc <IMMU.O> for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday.

Gilead nears deal to buy Immunomedics for more than $20 bln -WSJ

Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

BRIEF-Immunomedics Announces Positive Results From Study Of Trodelvy™ In Previously-Treated Patients With Metastatic Triple-Negative Breast Cancer

* IMMUNOMEDICS ANNOUNCES POSITIVE RESULTS FROM PHASE 3 ASCENT STUDY OF TRODELVY™ IN PREVIOUSLY-TREATED PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)

BRIEF-Immunomedics Says Harout Semerjian Decided To Step Down From Role As President And CEO

* IMMUNOMEDICS ANNOUNCES LEADERSHIP CHANGE AND PROVIDES BUSINESS UPDATE AMID COVID-19

BRIEF-Immunomedics To Present New Trodelvy Data In Non-Breast Cancer Indications At 2020 ASCO Virtual Meeting

* IMMUNOMEDICS TO PRESENT NEW TRODELVY™ DATA IN NON-BREAST CANCER INDICATIONS AT THE 2020 ASCO VIRTUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Immunomedics Reports Q1 Loss Per Share Of $0.44

* IMMUNOMEDICS REPORTS FIRST QUARTER 2020 RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Immunomedics Announces Commercial Availability Of Trodelvy™ In United States

* IMMUNOMEDICS ANNOUNCES COMMERCIAL AVAILABILITY OF TRODELVY™ IN UNITED STATES Source text for Eikon: Further company coverage:

BRIEF-Immunomedics Announces Pricing Of Public Offering Of Common Stock

* ANNOUNCED PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 14,736,860 SHARES OF ITS COMMON STOCK AT A PRICE OF $28.50 PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Immunomedics Announces Proposed Public Offering Of Common Stock

* IMMUNOMEDICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-FDA Grants Accelerated Approval For Immunomedics’ Trodelvy In Previously-Treated Breast Cancer

* FDA GRANTS ACCELERATED APPROVAL FOR IMMUNOMEDICS’ TRODELVY IN PREVIOUSLY-TREATED METASTATIC TRIPLE-NEGATIVE BREAST CANCER

FDA grants accelerated approval for Immunomedics' breast cancer therapy

Immunomedics Inc won an accelerated approval from the U.S. Food and Drug Administration for Trodelvy, its therapy for a form of invasive breast cancer that has worsened despite two prior rounds of treatment, the company said on Wednesday.

Immunomedics wins U.S. FDA approval for breast cancer therapy

Immunomedics Inc on Wednesday won the U.S. Food and Drug Administration approval for its therapy for a form of breast cancer that has worsened despite two prior rounds of treatment, according to the therapy's label from the agency.

BRIEF-FDA Approves Immunomedics' Trodelvy To Treat Adults With Metastatic Triple-Negative Breast Cancer

* FDA - APPROVES IMMUNOMEDICS' TRODELVY TO TREAT ADULTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER WHO HAVE GOT AT LEAST 2 PRIOR THERAPIES FOR METASTATIC DISEASE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up